The replacement of Cys (358) with a non-oxidizable mutant (Ser(358)) or PMK2 activators enhanced the sensitivity to oxidative stress and reduced tumor growth by reducing the flux into the PPP, rationalizing the inclusion of PKM2 activators as ideal therapeutics in combination with oxidative stress, thereby promoting therapeutics for cancer [54]. Here, PKM is linked to cancer.